|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600126446 |
|
最近更新日期: Date of Last Refreshed on: |
2026-06-09 14:16:10 |
|
注册时间: Date of Registration: |
2026-06-09 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
超细径高精度钬激光治疗机用于输尿管软镜碎石的有效性和安全性的前瞻性、单中心、单组目标值临床试验 |
|
Public title: |
A prospective, single-center, single-arm objective value clinical trial on the efficacy and safety of ultra-fine diameter high-precision holmium laser therapeutic apparatus in flexible ureteroscopic lithotripsy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
超细径高精度钬激光治疗机用于输尿管软镜碎石的有效性和安全性的前瞻性、单中心、单组目标值临床试验 |
|
Scientific title: |
A prospective, single-center, single-arm objective value clinical trial on the efficacy and safety of ultra-fine diameter high-precision holmium laser therapeutic apparatus in flexible ureteroscopic lithotripsy |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
邓春暖 |
研究负责人: |
许可慰 |
|
Applicant: |
Deng Chunnuan |
Study leader: |
Xu Kewei |
|
申请注册联系人电话: Applicant telephone: |
+86 135 1652 2052 |
研究负责人电话:
Study leader's |
+86 136 3233 1628 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
dengchn3@mail2.sysu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
xukewei@mail.sysu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省广州市越秀区沿江西路107号 |
研究负责人通讯地址: |
广东省广州市越秀区沿江西路107号 |
|
Applicant address: |
107 Yanjiang Xi Road, Yuexiu District, Guangzhou City, Guangdong Province |
Study leader's address: |
107 Yanjiang Xi Road, Yuexiu District, Guangzhou City, Guangdong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中山大学孙逸仙纪念医院 |
||
|
Applicant's institution: |
Sun Yat-sen Memorial Hospital, Sun Yat-sen University |
||
|
研究负责人所在单位: |
中山大学孙逸仙纪念医院 |
||
|
Affiliation of the Leader: |
Sun Yat-sen Memorial Hospital, Sun Yat-sen University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
SYSKY-2026-248-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中山大学孙逸仙纪念医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee, Sun Yat-sen Memorial Hospital, Sun Yat-sen University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-03-27 00:00:00 | ||
|
伦理委员会联系人: |
区柳珊 |
||
|
Contact Name of the ethic committee: |
Ou Liushan |
||
|
伦理委员会联系地址: |
中国广东省广州市沿江西路107路 |
||
|
Contact Address of the ethic committee: |
No.107 Yanjiangxi Road, Guangzhou, Guangdong, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 8133 2587 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中山大学孙逸仙纪念医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Sun Yat-sen Memorial Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国广东省广州市沿江西路107路 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.107 Yanjiangxi Road, Guangzhou, Guangdong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家重点研发计划 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Key Research and Development Program of China |
||||||||||||||||||||||
|
研究疾病: |
泌尿系结石 |
||||||||||||||||||||||
|
Target disease: |
Urolithiasis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
通过连续入组19例患者,探讨超细径高精度钬激光治疗机用于输尿管软镜碎石的有效性及安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
Nineteen consecutive enrolled patients were included to investigate the efficacy and safety of an ultra-fine diameter high-precision holmium laser lithotripter in flexible ureteroscopic lithotripsy. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.18≤年龄≤75 岁,性别不限,能够耐受手术; 2.筛选期经影像学检查提示为上尿路结石,累计最大直径≤25mm且拟输尿管 软镜碎石治疗者; 3.自愿参加并签署知情同意书者。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Aged between 18 and 75 years old inclusive, of any gender, and capable of tolerating surgery; 2. Patients with upper urinary tract stones confirmed by imaging examinations during the screening period, whose maximum cumulative stone diameter <= 25 mm, and who are scheduled to receive flexible ureteroscopic lithotripsy; 3. Patients who voluntarily participate in this trial and sign the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
凡符合下列任何一项者,均不应参加试验: 1.任何泌尿系统解剖学因素引起的腔内手术无法进行; 2.怀疑或已确诊有前列腺癌、泌尿系统肿瘤者; 3.有出血性倾向或凝血功能障碍(凝血酶原时间延长1.5倍)及有血小板减少(PLT<80*10^9/L)、再障等出血性血液系统疾病者; 4.合并活动性、全身性、感染性疾病者; 5.严重脊柱畸形、严重髋关节畸形,截石位困难; 6.筛选期ALT、AST大于正常值上限1.5倍者; 7.有尿路严重感染、麻醉不耐受等手术禁忌者; 8.已知对产品材质过敏者; 9.有精神疾病或病史者; 10.妊娠及哺乳期妇女以及3个月内有妊娠计划者; 11.研究者认为不宜参加本临床试验者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Subjects meeting any of the following criteria shall be excluded from this trial: 1. Presence of any anatomical abnormality of the urinary system that renders intracavitary surgery unfeasible; 2. Suspected or confirmed prostate cancer or other urinary tract malignancies; 3. Bleeding diathesis, coagulation disorders (prothrombin time prolonged to 1.5 times the upper limit of normal), thrombocytopenia (PLT < 80×10?/L), aplastic anemia or other hematologic diseases associated with bleeding risks; 4. Concurrent active systemic infectious diseases; 5. Severe spinal or hip deformities precluding placement in the lithotomy position; 6. Alanine transaminase (ALT) or aspartate transaminase (AST) levels exceeding 1.5 times the upper limit of normal during the screening phase; 7. Contraindications to surgery including severe urinary tract infection or intolerance to anesthesia; 8. Known hypersensitivity to the materials of the investigational device; 9. Current or past history of psychiatric disorders; 10. Pregnant or lactating women, and females planning pregnancy within 3 months; 11. Subjects deemed inappropriate for enrollment in this clinical trial by the investigator. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-06-15 00:00:00至 To 2027-05-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-06-15 00:00:00 至 To 2026-12-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF,EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF,EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |